Retina

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.

New research links genetic risk for schizophrenia to retinal thinning, suggesting early indicators of the disorder may be found in retinal morphology.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.

Neurotech partners with Cencora for the U.S. launch of ENCELTO, the first FDA-approved treatment for MacTel, enhancing patient access and support.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Celebrating a half-century of progress with Ophthalmology Times.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.